Investigation of the Correlation Between the Polymorphism/Expression Level of RANTES and Its Receptor CCR5 Gene Promoter and Type 2 Diabetes Mellitus

References

• Esquivel Zuniga R, DeBoer MD. Prediabetes in adolescents: prevalence, management and diabetes prevention strategies. Diabetes Metab Syndr Obes. 2021;14:4609–4619. doi:10.2147/DMSO.S284401
   PubMed Web of Science ®Google Scholar
• Saeedi P, Salpea P, Karuranga S, et al. Mortality attributable to diabetes in 20-79 years old adults, 2019 estimates: results from the international diabetes federation diabetes atlas. Diabetes Res Clin Pract. 2020;162:108086. doi:10.1016/j.diabres.2020.108086
   PubMed Web of Science ®Google Scholar
• Williams R, Karuranga S, Malanda B, et al. Global and regional estimates and projections of diabetes-related health expenditure: results from the international diabetes federation diabetes atlas. Diabetes Res Clin Pract. 2020;162:108072. doi:10.1016/j.diabres.2020.108072
   PubMed Web of Science ®Google Scholar
• Keshavarzi F, Golsheh S. IRS1- rs10498210 G/A and CCR5-59029 A/G polymorphisms in patients with type 2 diabetes in Kurdistan. Mol Genet Genomic Med. 2019;7(5):e631. doi:10.1002/mgg3.631
   PubMed Web of Science ®Google Scholar
• Fernández-Real JM, Pickup JC. Innate immunity, insulin resistance and type 2 diabetes. Trends Endocrinol Metab. 2008;19(1):10–16. doi:10.1016/j.tem.2007.10.004
   PubMed Web of Science ®Google Scholar
• O’Brien PD, Hinder LM, Parlee SD, et al. Dual CCR2/CCR5 antagonist treatment attenuates adipose inflammation, but not microvascular complications in ob/ob mice. Diabetes Obes Metab. 2017;19(10):1468–1472. doi:10.1111/dom.12950
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang X, Dong J, et al. Association of chemokine ligand 5/chemokine receptor 5 gene promoter polymorphisms with diabetic microvascular complications: a meta-analysis. J Diabetes Investig. 2016;7(2):212–218. doi:10.1111/jdi.12397
   PubMed Web of Science ®Google Scholar
• Zhu J, Wilding JPH. The 1α,25(OH)2D3 analogs ZK159222 and ZK191784 show anti-inflammatory properties in macrophage-induced preadipocytes via modulating the NF-κB and MAPK signaling. Diabetes Metab Syndr Obes. 2020;13:1715–1724. doi:10.2147/DMSO.S245080
   PubMed Web of Science ®Google Scholar
• Jamali Z, Nazari M, Khoramdelazad H, et al. Expression of CC chemokines CCL2, CCL5, and CCL11 is associated with duration of disease and complications in type-1 diabetes: a study on Iranian diabetic patients. Clin Lab. 2013;59(9–10):993–1001. doi:10.7754/Clin.Lab.2012.120810
   PubMed Web of Science ®Google Scholar
• Chou SY, Ajoy R, Changou CA, Hsieh YT, Wang YK, Hoffer B. CCL5/RANTES contributes to hypothalamic insulin signaling for systemic insulin responsiveness through CCR5. Sci Rep. 2016;6:37659. doi:10.1038/srep37659
   PubMed Web of Science ®Google Scholar
• Inayat H, Azim MK, Baloch AA. Analysis of inflammatory gene expression profile of peripheral blood leukocytes in type 2 diabetes. Immunol Invest. 2019;48(6):618–631. doi:10.1080/08820139.2019.1586917
   PubMed Web of Science ®Google Scholar
• Kochetova OV, Avzaletdinova DS, Morugova TV, Mustafina OE. Chemokine gene polymorphisms association with increased risk of type 2 diabetes mellitus in Tatar ethnic group, Russia. Mol Biol Rep. 2019;46(1):887–896. doi:10.1007/s11033-018-4544-6
   PubMed Web of Science ®Google Scholar
• Mohamed HG, Idris SB, Ahmed MF, et al. Influence of type 2 diabetes on local production of inflammatory molecules in adults with and without chronic periodontitis: a cross-sectional study. BMC Oral Health. 2015;15:86. doi:10.1186/s12903-015-0073-z
   PubMed Web of Science ®Google Scholar
• Lohmann T, Laue S, Nietzschmann U, et al. Reduced expression of Th1-associated chemokine receptors on peripheral blood lymphocytes at diagnosis of type 1 diabetes. Diabetes. 2002;51(8):2474–2480. doi:10.2337/diabetes.51.8.2474
   PubMed Web of Science ®Google Scholar
• Dworacka M, Krzyżagórska E, Iskakova S, Bekmukhambetov Y, Urazayev O, Dworacki G. Increased circulating RANTES in type 2 diabetes. Eur Cytokine Netw. 2014;25(3):46–51. doi:10.1684/ecn.2014.0355
   PubMed Web of Science ®Google Scholar
• Tokarz A, Konkolewska M, Kuśnierz-Cabala B, et al. Retinopathy severity correlates with RANTES concentrations and CCR 5-positive microvesicles in diabetes. Folia Med Cracov. 2019;59(3):95–112. doi:10.24425/fmc.2019.131139
   PubMedGoogle Scholar
• Longo PL, Artese HP, Rabelo MS, et al. Serum levels of inflammatory markers in type 2 diabetes patients with chronic periodontitis. J Appl Oral Sci. 2014;22(2):103–108. doi:10.1590/1678-775720130540
   PubMed Web of Science ®Google Scholar
• Pfleger C, Kaas A, Hansen L, et al; Hvidøre Study Group On Childhood Diabetes. Relation of circulating concentrations of chemokine receptor CCR5 ligands to C-peptide, proinsulin and HbA1c and disease progression in type 1 diabetes. Clin Immunol. 2008;128(1):57–65. doi:10.1016/j.clim.2008.03.458
   PubMed Web of Science ®Google Scholar
• Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002;106(16):2067–2072. doi:10.1161/01.CIR.0000034509.14906.AE
   PubMed Web of Science ®Google Scholar
• Carvalho-Pinto C, García MI, Gómez L, et al. Leukocyte attraction through the CCR5 receptor controls progress from insulitis to diabetes in non-obese diabetic mice. Eur J Immunol. 2004;34(2):548–557. doi:10.1002/eji.200324285
   PubMed Web of Science ®Google Scholar
• Boon J, Hoy AJ, Stark R, et al. Ceramides contained in LDL are elevated in type 2 diabetes and promote inflammation and skeletal muscle insulin resistance. Diabetes. 2013;62(2):401–410. doi:10.2337/db12-0686
   PubMed Web of Science ®Google Scholar
• Hui N, Barter PJ, Ong KL, Rye KA. Altered HDL metabolism in metabolic disorders: insights into the therapeutic potential of HDL. Clin Sci. 2019;133(21):2221–2235. doi:10.1042/CS20190873
   Web of Science ®Google Scholar
• Jonas K, Magoń W, Podolec P, Kopeć G. Triglyceride-to-high-density lipoprotein cholesterol ratio and systemic inflammation in patients with idiopathic pulmonary arterial hypertension. Med Sci Monit. 2019;25:746–753. doi:10.12659/MSM.912766
   PubMed Web of Science ®Google Scholar
• Sieg SF, Bazdar DA, Zidar D, Freeman M, Lederman MM, Funderburg NT. Highly oxidized low-density lipoprotein mediates activation of monocytes but does not confer interleukin-1β secretion nor interleukin-15 transpresentation function. Immunology. 2020;159(2):221–230. doi:10.1111/imm.13142
   PubMed Web of Science ®Google Scholar
• Li Q, Wang D, Wang Y, Xu Q. Simvastatin down regulates mRNA expression of RANTES and CCR5 in posttransplant renal recipients with hyperlipidemia. Transplant Proc. 2006;38(9):2899–2904. doi:10.1016/j.transproceed.2006.08.136
   PubMed Web of Science ®Google Scholar
• Hyde CL, Macinnes A, Sanders FA, et al. Genetic association of the CCR5 region with lipid levels in at-risk cardiovascular patients. Circ Cardiovasc Genet. 2010;3(2):162–168. doi:10.1161/CIRCGENETICS.109.897793
   PubMedGoogle Scholar
• Słomiński B, Ławrynowicz U, Ryba-Stanisławowska M, Skrzypkowska M, Myśliwska J, Myśliwiec M. CCR5-Δ32 polymorphism is a genetic risk factor associated with dyslipidemia in patients with type 1 diabetes. Cytokine. 2019;114:81–85. doi:10.1016/j.cyto.2018.11.005
   PubMed Web of Science ®Google Scholar
• Cipriani S, Francisci D, Mencarelli A, et al. Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice. Circulation. 2013;127(21):2114–2124. doi:10.1161/CIRCULATIONAHA.113.001278
   PubMed Web of Science ®Google Scholar
• Wu Y, Liu F, Zhang X, Shu L. Insulin modulates cytokines expression in human periodontal ligament cells. Arch Oral Biol. 2014;59(12):1301–1306. doi:10.1016/j.archoralbio.2014.07.002
   PubMed Web of Science ®Google Scholar
• Ghanim H, Korzeniewski K, Sia CL, et al. Suppressive effect of insulin infusion on chemokines and chemokine receptors. Diabetes Care. 2010;33(5):1103–1108. doi:10.2337/dc09-2193
   PubMed Web of Science ®Google Scholar
• Yang B, Houlberg K, Millward A, Demaine A. Polymorphisms of chemokine and chemokine receptor genes in type 1 diabetes mellitus and its complications. Cytokine. 2004;26(3):114–121. doi:10.1016/j.cyto.2004.01.005
   PubMed Web of Science ®Google Scholar
• Zhernakova A, Alizadeh BZ, Eerligh P, et al. Genetic variants of RANTES are associated with serum RANTES level and protection for type 1 diabetes. Genes Immun. 2006;7(7):544–549. doi:10.1038/sj.gene.6364326
   PubMed Web of Science ®Google Scholar
• Herder C, Illig T, Baumert J, et al. RANTES/CCL5 gene polymorphisms, serum concentrations, and incident type 2 diabetes: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Eur J Endocrinol. 2008;158(5):R1–R5. doi:10.1530/EJE-07-0686
   PubMed Web of Science ®Google Scholar
• Yadav AK, Kumar V, Dutta P, Bhansali A, Jha V. Variations in CCR5, but not HFE, ELMO1, or SLC12A3, are associated with susceptibility to kidney disease in north Indian individuals with type 2 diabetes. J Diabetes. 2014;6(6):547–555. doi:10.1111/1753-0407.12128
   PubMed Web of Science ®Google Scholar
• Shieh B, Liau YE, Hsieh PS, Yan YP, Wang ST, Li C. Influence of nucleotide polymorphisms in the CCR2 gene and the CCR5 promoter on the expression of cell surface CCR5 and CXCR4. Int Immunol. 2000;12(9):1311–1318. doi:10.1093/intimm/12.9.1311
   PubMed Web of Science ®Google Scholar
• Buraczynska M, Zukowski P, Wacinski P, Berger-Smyka B, Dragan M, Mozul S. Chemotactic cytokine receptor 5 gene polymorphism: relevance to microvascular complications in type 2 diabetes. Cytokine. 2012;58(2):213–217. doi:10.1016/j.cyto.2012.01.007
   PubMed Web of Science ®Google Scholar